Login to Your Account



Macrophage to make tumors more susceptible to I-O therapies

By Nuala Moran
Staff Writer

Monday, January 9, 2017
newco_news_resized.jpg

LONDON – Macrophage Pharma Ltd. has raised £9 million (US$10.9 million) in a series A to commercialize a small-molecule immuno-oncology technology originally developed by chromatin biology specialist, Chroma Therapeutics Ltd.

To continue reading subscribe now to Latest News

Learn More about Latest News

Already a subscriber? Sign In or Buy now to activate your subscription